Efficacy of infliximab in acute severe ulcerative colitis: A single-centre experience

Table 1 Baseline characteristics and demographics of 44 patients with acute severe ulcerative colitis receiving infliximab n (%)

Characteristic	All patients (n = 44)
Age at index admission1	35.7 ± 15.9
Female	16 (36.4)
Extent of disease (Montreal classification)
E1 (limited to rectum)	2 (4.5)
E2 (distal to splenic flexure)	13 (29.5)
E3 (proximal to splenic flexure)	29 (65.9)
Current or previous smoker	18 (40.9)
Prescribed oral 5-ASA on admission	24 (54.5)
Prescribed thiopurine on admission	14 (31.8)
Median disease duration, in days, prior to first IFX infusion (IQR)	409 (16.25 to 1896.5)
First presentation of UC	12 (27.3)
Mean CRP (mg/L) on day of admission1	90.1 ± 81.9
CRP ≤ 5 on day of admission	6 (13.6)
Mean number of stools per day on admission1	12.1 ± 5.8

¹Data are presented as mean ± SD. UC: Ulcerative colitis; IQR: Interquartile range; 5-ASA: 5-aminosalicylate; CRP: C-reactive protein; IFX: Infliximab.

Table 2 Clinical characteristics and demographics of 44 patients with acute severe ulcerative colitis receiving infliximab, according to colectomy status after index admission and at last point of follow-up n (%)

	Colectomy status after index admission			Colectomy status at last point of follow-up
	Colectomy during index admission (n = 9)	Discharged colectomy-free (n = 35)	P value2	Colectomy during index admission or follow-up (n = 15)	Colectomy-free survival (n = 29)	P value2
Age at index admission1	45.6 ± 24.7	33.2 ± 12.1	0.18	42.2 ± 21.4	32.4 ± 11.3	0.11
Male	7 (77.8)	21 (60.0)	0.45	10 (66.7)	18 (62.1)	1.0
First presentation of UC	5 (55.6)	7 (20.0)	0.09	6 (40.0)	6 (20.7)	0.28
Disease extent	E1: 0 (0)	E1: 2 (5.7)		E1: 2 (13.3)	E1: 0 (0)
	E2: 3 (33.3)	E2: 10 (28.6)		E2: 3 (20.0)	E2: 10 (34.5)
	E3: 6 (66.7)	E3: 23 (65.7)	0.753	E3: 10 (66.7)	E3: 19 (65.5)	0.103
Current or previous smoker	4 (44.4)	14 (40.0)	1.0	6 (40.0)	12 (41.4)	1.0
Prescribed oral 5-ASA on admission	3 (33.3)	21 (60.0)	0.26	8 (53.3)	16 (55.2)	1.0
Prescribed thiopurine on admission	0 (0)	14 (40.0)	0.04	3 (20.0)	11 (37.9)	0.31
CRP (mg/L): day 01	163 ± 62.5	71 ± 76	0.002	111.0 ± 83.0	79.0 ± 80.6	0.23
CRP (mg/L): day1	96 ± 69	39 ± 41.5	0.04	65.3 ± 65.5	42.9 ± 44.3	0.25
Number of stools per day: day 01	13.3 ± 5.6	11.7 ± 5.9	0.46	13.0 ± 5.7	11.6 ± 5.9	0.44
Number of stools per day: day 31	8.7 ± 4.6	6.5 ± 3.3	0.21	7.7 ± 4.2	6.6 ± 3.3	0.39
Met Travis criteria at day 3	9 (100)	15 (42.9)	0.002	10 (66.7)	14 (48.3)	0.34
Received IFX on day 5 or sooner	1 (11.1)	11 (31.4)	0.41

¹Data are presented as mean ± SD;

²Independent samples t-test for continuous data and Fisher’s exact test for categorical data;

³χ² for trend. UC: Ulcerative colitis; 5-ASA: 5-aminosalicylate; CRP: C-reactive protein; IFX: Infliximab.